641 692
survival analysis of the randomized phase 3 GETUG-AFU15 trial.
Eur Urol 2016;70:256–62
.
[60]
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737–46.[61]
James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lan- cet 2016;387:1163–77.
[62]
Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015;33:3199–212.
[63]
Collette L, de Reijke TM, Schroder FH. Prostate specific antigen: a prognosticmarker of survival in good prognosis metastatic prostate cancer? (EORTC 30892) Eur Urol 2003;44:182–9, discussion 189.
[64]
Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148–59.
[65]
Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136–9, dis- cussion 139.
[66]
Conde FA, Aronson WJ. Risk factors for male osteoporosis. Urol Oncol 2003;21:380–3.
[67]
Saylor PJ, Smith MR. Metabolic complications of androgen depri- vation therapy for prostate cancer. J Urol 2009;181:1998–2006, discussion 2007-8.
[68]
Faris JE, Smith MR. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 2010;17:240–6.
[69]
Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmeta- static prostate cancer. J Clin Oncol 2005;23:2918–25.
[70]
Smith MR, Cook R, Lee KA, Nelson JB. Disease and host character- istics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011;117:2077–85.
[71]
Crawford ED, Stone NN, Yu EY, et al. Challenges and recommenda- tions for early identification of metastatic disease in prostate cancer. Urology 2014;83:664–9.
[72]
Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemo- therapy trials for hormone-refractory prostate cancer: a South- west Oncology Group report. J Clin Oncol 1994;12:1868–75.
[73]
Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993;11:2167–72.
[74]
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–48.
[75]
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy- naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152–60.
[76]
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–33.
[77]
Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099–105.[78]
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.
[79]
Eisenberger M, Garrett-Mayer ES, Ou Yang Y, de Wit R, Tannock I, Armstrong AJ. A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC). J Clin Oncol 2007;25(Suppl), abstract 5058.
[80]
Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010;16:203–11.
[81]
Horgan AM, Seruga B, Pond GR, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol 2014;5:119–26.
[82]
Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2- Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013;14:117–24.
[83]
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213–23.
[84]
Hoskin P, Sartor O, O’Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant pros- tate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15:1397–406.
[85]
Gillessen S, Omlin A, Attard G, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015;26:1589–604.
[86]
Pezaro CJ, Omlin A, Lorente D, et al. Visceral disease in castration- resistant prostate cancer. Eur Urol 2014;65:270–3.
[87]
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028–38.
[88]
Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2004;91: 1425–7.
[89]
Ohlmann CH, O¨ zgu¨ r E, Wille S, Engelmann U, Heidenreich A. Second-line chemotherapy with docetaxel for prostate-specific antigen relapse in men with hormone refractory prostate cancer previously treated with docetaxel based chemotherapy. Eur Urol Suppl 2006;5, abstract 289.
[90]
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus caba- zitaxel or mitoxantrone for metastatic castration-resistant pros- tate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147–54.
[91]
Resnick MJ, Lacchetti C, Bergman J, et al. Prostate cancer survi- vorship care guideline: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 2015;33: 1078–85.[92]
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and in- creased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.
[93]
Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treat- ment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, dou- ble-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983–92.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 6 3 0 – 6 4 2
641